Shamonda Virus: First Human Case in France (2026)

Shamonda Virus: First Human Case in France (2026) — What We Know

On October 22, 2026, France announced something never recorded before: the first documented human infection with Shamonda virus, a pathogen previously found only in animals. The patient — a man in his 60s from the Lyon area with a severely weakened immune system — died in early October while being treated for a serious illness at a Lyon hospital. French authorities believe he was infected through the bite of a tiny midge in eastern France, where the virus had circulated among livestock through spring and summer.

This guide explains what Shamonda virus is, where it came from, what happened in France, and — honestly — what is still unknown about its effects on people, how it is detected, and what precautions make sense. Both the World Health Organization and the European Centre for Disease Prevention and Control are monitoring the situation — the same international coordination seen during the emergence of new COVID variants in 2026 — and their assessments shape everything below. Medically reviewed by Dr. Ata Ullah, MD (Medicine).

What Causes Shamonda Virus Infection

Shamonda virus (SHAV) is the direct cause of Shamonda infection: an RNA virus of the genus Orthobunyavirus (family Peribunyaviridae), in the Simbu serogroup of insect-borne viruses, as described by the World Organisation for Animal Health, that also includes Schmallenberg virus. First isolated from Nigerian cattle in 1965, it was found sporadically in African and Japanese herds — and never in a human being until October 2026.

The virus reaches new hosts through the bite of infected Culicoides midges — minute biting insects that feed on the blood of cattle and other ruminants. Cattle are the primary hosts; sheep, goats, horses, and alpacas have also been infected. In 2026 the virus appeared in Europe for the first time: a new variant was identified on July 31, 2026, after disease investigations on cattle farms in Germany and Switzerland. Two European lineages now circulate — SHAV-EU1 and SHAV-EU2 — and by late October 2026 the virus had been found in farm animals in 14 western European countries.

Investigators believe the French patient was infected by a midge bite in eastern France, where the virus had circulated among livestock through spring and summer 2026. French authorities call it an exceptional convergence — a widespread animal virus meeting a profoundly susceptible host — not evidence of spread among people.

How Shamonda Virus Behaves in the Body

What the virus does inside a human body is still largely unknown: exactly one case exists. In adult cattle, it typically causes a short illness: fever, acute diarrhoea, lethargy, and a drop in milk production, with most animals recovering. The more serious documented effect is reproductive: infection during pregnancy can cause abortion or congenital malformations in calves. A cluster of malformed calves in southern Japan (2015–2016) was traced to Shamonda infection in the womb.

The French patient developed neurological complications before death, which French authorities say were very likely linked to the infection — though investigations continue into whether the virus caused or merely contributed to the death. This is biologically plausible: Shamonda’s close relative Shuni virus, found in the same 1960s Nigerian surveys, has been detected in people with neurological illness in South Africa, suggesting this virus family can occasionally reach the human nervous system.

As Tom Solomon of Britain’s Pandemic Institute noted, much remains unknown — whether healthy people can be infected without symptoms, what symptoms the virus would normally cause, and how often it might cause serious disease. With a single case in a severely immunocompromised patient, no general conclusions about human disease can yet be drawn. This pattern of an animal virus reaching people echoes other 2026 outbreak stories, including Central Africa’s Bundibugyo Ebola emergence.

Prevention: Avoiding Midge Bites and Animal Exposure

Because there is no vaccine against Shamonda virus for people — and no specific treatment — prevention rests on avoiding the bite of infected midges and limiting close contact with potentially infected livestock in affected regions.

First, reduce midge bites. Culicoides midges are most active around dawn and dusk and breed in damp organic matter such as manure and mud. In affected rural European regions, wear long sleeves and trousers during peak midge hours, apply repellent with DEET or picaridin to exposed skin, and sleep with window screens or nets where midges are abundant.

Second, take sensible precautions around livestock. People who work with cattle, sheep, goats, or horses in the affected European countries should wear gloves when handling animals or birth products, wash hands thoroughly afterwards, and report unusual herd illness (fever, diarrhoea, milk-yield drops, abortions or malformed calves) to veterinary authorities — animal surveillance is currently the main early-warning system.

Third, travellers to rural Europe need no special measures beyond standard insect-bite precautions. The WHO describes this as an isolated case unlikely to spread further, and there is no evidence of person-to-person transmission — so no isolation, masking, or travel restrictions are warranted.

Finally, support the surveillance that protects everyone. Because Shamonda is not subject to official EU control measures, early warning depends on farmers and veterinarians reporting unusual herd illness and on laboratories sharing sequence data — the cooperation that flagged the European emergence. The ECDC’s expanded testing will gradually reveal whether the French case was truly unique.

Symptoms: What We Know So Far

Honesty requires stating this plainly: there is no established human symptom profile for Shamonda virus — only one human infection has ever been documented. Everything below is drawn from that single French case and from the virus’s long-observed behaviour in animals.

In the French patient, the reported clinical feature was neurological complications developing during hospitalisation for a separate serious illness, in a man whose immune system was severely compromised. French authorities described these complications as very likely linked to the infection, but the investigation into the exact role of the virus is still underway.

In animals, the picture is clearer. Adult cattle typically develop a brief febrile illness — fever, acute diarrhoea, lethargy, and reduced milk production — usually resolving without intervention. The concerning manifestation is reproductive: abortions, stillbirths, and calves born with congenital malformations when infection occurs during pregnancy. Whether any of this translates to human pregnancy risk is entirely unknown; there is no data.

Equally important is what remains unknown. We do not know whether healthy people can be infected without symptoms, what a “typical” human case would look like, or how often serious disease might occur. Decades of circulation in Africa and Asia with no documented human case suggests human infection is rare — but the virus’s new European footprint means surveillance is warranted.

The precedent worth knowing is Shuni virus, Shamonda’s close Simbu-group relative, found in South African patients with neurological illness. That does not prove Shamonda behaves the same way, but it keeps open the possibility that this virus family can occasionally invade the nervous system. Anyone — especially anyone immunocompromised — who develops unexplained fever with neurological symptoms after midge exposure in affected rural Europe should seek prompt medical care and mention the exposure, so clinicians can consider arboviral testing without any further delay.

Tests and Diagnosis

Because Shamonda virus has only just entered human medicine, there is no routine commercial test for it, and diagnosis currently depends on specialised laboratory investigation — essentially the same path that identified the French case. Understanding that path helps explain both what confirmation looks like and why wider case-finding is now beginning.

The French case was detected through advanced laboratory workup in Lyon. For a virus never before seen in humans, identification typically relies on molecular methods: polymerase chain reaction (PCR) assays that detect viral genetic material, followed by sequencing to confirm the exact lineage — in this instance, consistent with the European Shamonda lineages circulating in livestock. Sequencing matters because it distinguishes Shamonda from its many close relatives in the Simbu serogroup and confirms the epidemiological link to the animal outbreak.

Serological testing — detecting antibodies in blood — can show whether a person was infected in the past. However, human antibody tests for Shamonda are not standardised or widely available, and cross-reactivity with related orthobunyaviruses can complicate interpretation. The ECDC is now coordinating with an EU reference laboratory to expand testing and check for other potential cases, while Germany’s Friedrich Loeffler Institute publishes the virus’s animal-disease profile.

In animals, diagnosis is more established: veterinary laboratories use PCR on blood or tissue and serology on herd samples, and the 2026 European emergence was tracked this way. For people, the practical message is simple — there is no test to request at a clinic today. A suspected case would be investigated through hospital infectious-disease specialists and national reference laboratories.

Treatment and the Emergency Medicines Guide

There is no specific antiviral treatment for Shamonda virus and no vaccine for people — unlike influenza, where new mRNA vaccines arrived in 2026. This is unsurprising: until October 2026 the virus was considered incapable of infecting humans at all, so no human therapeutics were ever developed. If further human cases were ever identified, care would be supportive — managing fever, maintaining hydration, and treating complications.

The French patient was already receiving hospital treatment for a serious underlying illness when the infection was detected, and the published reports do not describe any Shamonda-specific therapy being given, because none exists.

Emergency Medicines Guide — Symptom → Medicine Class

The following is general information about medicine classes doctors commonly use for the symptoms that might accompany a suspected arboviral illness — it is not a Shamonda treatment protocol, because none exists. Generic names only; dosage must come from your doctor or pharmacist.

  • Fever and pain → antipyretic/analgesic classes such as paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, as directed by a clinician.
  • Dehydration from fever or diarrhoea → oral rehydration salts; intravenous fluids in hospital settings if dehydration is severe.
  • Nausea and vomiting → antiemetic classes as prescribed.
  • Seizures or severe neurological symptoms → emergency hospital care; anticonvulsant classes are administered only by medical teams.
  • Secondary bacterial infection → antibiotic classes only if a doctor confirms a bacterial complication; antibiotics do not act on viruses.

Do not self-treat a suspected exotic infection. Anyone with unexplained neurological symptoms after midge exposure in affected areas needs urgent in-person medical evaluation.

What to Eat

There is no specific diet that treats or prevents Shamonda virus infection — no food neutralises an arbovirus. The honest nutritional advice is therefore the general kind that supports immune function and recovery from any febrile illness, which is worth stating plainly rather than dressing up as virus-specific guidance.

During any feverish illness, the priorities are fluids and energy. Fever and diarrhoea deplete water and electrolytes, so frequent small volumes of water, oral rehydration solutions, broths, and soups matter most. Easily digested, nutrient-dense foods — cooked grains such as rice and oats, lentils, eggs, yoghurt, bananas, and cooked vegetables — supply steady energy without taxing an unsettled stomach. Protein deserves emphasis during recovery: the immune system is protein-hungry, and prolonged poor intake slows convalescence after any significant illness. Small, frequent meals are easier to tolerate than large ones.

For general immune support, a varied diet rich in fruits and vegetables provides vitamin C, vitamin A precursors, and zinc. None of these has any demonstrated effect against Shamonda virus specifically, and no supplement should be treated as protection against infection. People with chronic illness or immunocompromise — the group most relevant to the single known human case — should discuss any major dietary changes with their treating physician.

What to Avoid

Just as there is no diet that treats Shamonda infection, there is no food that must be shunned because of it — but several avoidances are worth stating for anyone dealing with a suspected arboviral illness or recovering from one. Avoid alcohol during any febrile illness: it dehydrates, disrupts sleep, and can interact with fever-reducing medicines. Do not self-medicate with antibiotics “just in case” — they do nothing against viruses. Avoid unverified “cures” marketed online after outbreak news; emerging infections reliably attract scams, and none has any evidence behind it.

Do not dismiss genuine warning signs: severe headache, confusion, neck stiffness, weakness, or seizures after insect exposure warrant urgent care. And avoid panic-driven avoidance of the outdoors or of dairy and meat: the virus spreads through midge bites, not through food, and there is no evidence that properly handled animal products transmit it. Proportionate caution — bite prevention in affected rural areas — is the whole of what is currently warranted.

Frequently Asked Questions

What is Shamonda virus?
Shamonda virus is a midge-borne RNA virus of the Orthobunyavirus group that mainly infects cattle and other ruminants such as sheep, goats, and horses. First found in Nigerian cattle in 1965, it reached European livestock in 2026, and in October 2026 France reported the first documented human infection — a fatal case in a severely immunocompromised patient in Lyon.

Can Shamonda virus spread from person to person?
There is no evidence of person-to-person transmission. The only known human case is believed to have come from a midge bite, and the WHO describes it as an isolated case unlikely to spread further.

Should the general public be worried?
No. French authorities, the WHO, and the ECDC all state that no risk to the general population has been identified. The single case involved a severely immunocompromised patient — described by officials as exceptional.

Is there a vaccine or treatment?
No. Because the virus was considered incapable of infecting humans until October 2026, no human vaccine or antiviral was ever developed. Care for any future case would be supportive: fever management, hydration, and treatment of complications.

How can I protect myself?
Standard midge-bite precautions in affected rural Europe: long sleeves and trousers at dawn and dusk, repellent with DEET or picaridin, and window screens or nets. Livestock workers should use gloves and report unusual animal illness to veterinary authorities.

Could there be more undetected human cases?
It is unknown. We do not yet know whether healthy people can be infected without symptoms. European health agencies are now expanding testing to check for other potential cases, which should answer this question over time.

A Final Word

The Shamonda story is, at its heart, a reminder of how closely human and animal health are intertwined. A virus watched in cattle for sixty years met a profoundly vulnerable patient, and within days the finding was reported to the world with careful, honest framing: this is exceptional, the general public is not at risk, and investigations continue. If you live in or visit rural Europe, simple bite precautions are sensible; beyond that, no fear is warranted.

Reviewed by Dr. Ata Ullah

Dr. Ata Ullah — MBBS, MD Medicine, Physician Consultant. Dr. Ata Ullah is a Senior Medical Officer with extensive experience in internal medicine, dedicated to helping patients understand their health through clear, evidence-based guidance.

“Your Health, Our Responsibility.”

Medical Disclaimer: This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read on this site.

Online Consultation: Dr. Ata Ullah (MBBS, MD Medicine), Physician Consultant / Medical Specialist — WhatsApp: 0315 7148181 — Consultation Fees: $30